BNT162b2 COVID-19 vaccination elicits the expansion of CD16CD8 T cells endowed with natural killer cell features.

BACKGROUND

The Pfizer-BioNtech vaccine, also known as BNT162b2, was developed using a novel technology based on mRNA and protects against coronavirus disease 2019 (COVID-19) via induction of specific antibody and T-cell responses. Much less is known about the broader effects of this new class of vaccines on unconventional cellular components of the immune system.

OBJECTIVES

We aimed to characterize a subset of unconventional T cells emerging following BNT162b2 mRNA vaccination.

METHODS

Peripheral blood from a total of 30 human healthy individuals who received 2 doses of the BNT162b2 mRNA vaccine was collected for the analysis of T-cell compartment by using multiparametric flow cytometry and single-cell transcriptome analyses.

RESULTS

In the peripheral blood of individuals undergoing BNT162b2 vaccination, we observed a sizable fraction of CD8 T cells expressing CD16, a low-affinity FcR for IgG. These cells were severe acute respiratory coronavirus 2-specific, characterized by IFN-γ response gene transcripts and stimulation through CD16 and other natural killer (NK)-cell innate receptors elicited a functional response. Both CD16 and NKp30 could be induced on NKp80 CD8 T cells and the engagement of NKp80 in combination with CD16 resulted in synergic effects. CD16 CD8 T cells also showed a high expression of the inhibitory receptor G protein-coupled receptor 56 (GPR56), capable of limiting their activation via CD16.

CONCLUSIONS

These data indicate that BNT162b2 COVID-19 vaccination provides an additional large fraction of antibody-dependent cellular cytotoxicity (ADCC)-capable effector cells, endowed with innate functions and therefore able to potentially counteract a much wider array of diseases, including cancer.